All posts by medical

New Clues to Origin of Life on Earth From Meteorite Discovery – SciTechDaily

Artists concept of meteors impacting ancient Earth. Some scientists think such impacts may have delivered water and other molecules useful to emerging life on Earth. Credit: NASAs Goddard Space Flight Center Conceptual Image Lab

An international team has found sugars essential to life in meteorites. The new discovery adds to the growing list of biologically important compounds that have been found in meteorites, supporting the hypothesis that chemical reactions in asteroids the parent bodies of many meteorites can make some of lifes ingredients. If correct, meteorite bombardment on ancient Earth may have assisted the origin of life with a supply of lifes building blocks.

The team discovered ribose and other bio-essential sugars including arabinose and xylose in two different meteorites that are rich in carbon, NWA 801 (type CR2) and Murchison (type CM2). Ribose is a crucial component of RNA (ribonucleic acid). In much of modern life, RNA serves as a messenger molecule, copying genetic instructions from the DNA molecule (deoxyribonucleic acid) and delivering them to molecular factories within the cell called ribosomes that read the RNA to build specific proteins needed to carry out life processes.

Other important building blocks of life have been found in meteorites previously, including amino acids (components of proteins) and nucleobases (components of DNA and RNA), but sugars have been a missing piece among the major building blocks of life, said Yoshihiro Furukawa of Tohoku University, Japan, lead author of the study published in the Proceedings of the National Academy of Sciences on November 18, 2019. The research provides the first direct evidence of ribose in space and the delivery of the sugar to Earth. The extraterrestrial sugar might have contributed to the formation of RNA on the prebiotic Earth which possibly led to the origin of life.

This is a mosaic image of asteroid Bennu, from NASAs OSIRIS-REx spacecraft. The discovery of sugars in meteorites supports the hypothesis that chemical reactions in asteroids the parent bodies of many meteorites can make some of lifes ingredients. Credit: NASA/Goddard/University of Arizona

It is remarkable that a molecule as fragile as ribose could be detected in such ancient material,said Jason Dworkin, a co-author of the study at NASAs Goddard Space Flight Center in Greenbelt, Maryland. These results will help guide our analyses of pristine samples from primitive asteroids Ryugu and Bennu, to be returned by the Japan Aerospace Exploration Agencys Hayabusa2 and NASAs OSIRIS-REx spacecraft.

An enduring mystery regarding the origin of life is how biology could have arisen from non-biological chemical processes. DNA is the template for life, carrying the instructions for how to build and operate a living organism. However, RNA also carries information, and many researchers think it evolved first and was later replaced by DNA. This is because RNA molecules have capabilities that DNA lacks. RNA can make copies of itself without help from other molecules, and it can also initiate or speed up chemical reactions as a catalyst. The new work gives some evidence to support the possibility that RNA coordinated the machinery of life before DNA.

The sugar in DNA (2-deoxyribose) was not detected in any of the meteorites analyzed in this study, said Danny Glavin, a co-author of the study at NASA Goddard. This is important since there could have been a delivery bias of extraterrestrial ribose to the early Earth which is consistent with the hypothesis that RNA evolved first.

This is a model of the molecular structure of ribose and an image of the Murchison meteorite. Ribose and other sugars were found in this meteorite. Credit: Yoshihiro Furukawa

The team discovered the sugars by analyzing powdered samples of the meteorites using gas chromatography mass spectrometry, which sorts and identifies molecules by their mass and electric charge. They found that the abundances of ribose and the other sugars ranged from 2.3 to 11 parts per billion in NWA 801 and from 6.7 to 180 parts per billion in Murchison.

Since Earth is awash with life, the team had to consider the possibility that the sugars in the meteorites simply came from contamination by terrestrial life. Multiple lines of evidence indicate contamination is unlikely, including isotope analysis. Isotopes are versions of an element with different mass due to the number of neutrons in the atomic nucleus. For example, life on Earth prefers to use the lighter variety of carbon (12C) over the heavier version (13C). However, the carbon in the meteorite sugars was significantly enriched in the heavy 13C, beyond the amount seen in terrestrial biology, supporting the conclusion that it came from space.

The team plans to analyze more meteorites to get a better idea of the abundance of the extraterrestrial sugars. They also plan to see if the extraterrestrial sugar molecules have a left-handed or right-handed bias. Some molecules come in two varieties that are mirror images of each other, like your hands. On Earth, life uses left-handed amino acids and right-handed sugars. Since its possible that the opposite would work fine right-handed amino acids and left-handed sugars scientists want to know where this preference came from. If some process in asteroids favors the production of one variety over the other, then maybe the supply from space via meteorite impacts made that variety more abundant on ancient Earth, which made it more likely that life would end up using it.

###

Reference: Extraterrestrial ribose and other sugars in primitive meteorites by Yoshihiro Furukawa, Yoshito Chikaraishi, Naohiko Ohkouchi, Nanako O. Ogawa, Daniel P. Glavin, Jason P. Dworkin, Chiaki Abe and Tomoki Nakamura, 18 November 2019, Proceedings of the National Academy of Sciences.DOI: 10.1073/pnas.1907169116

The research was funded by a Japan Society for the Promotion of Science KAKENHI (science grant), the National Institutes of Natural Sciences Astrobiology Center, Japan, the Institute of Low Temperature Science, Hokkaido University, the Simons Foundation, and the NASA Astrobiology Institute, Goddard Center for Astrobiology. Jason Dworkin and Danny Glavin are members of the Goddard Center for Astrobiology team.

Continue reading here:
New Clues to Origin of Life on Earth From Meteorite Discovery - SciTechDaily

Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions – Business Wire

PALO ALTO, Calif.--(BUSINESS WIRE)--Immune-Onc Therapeutics, Inc. (Immune-Onc), a privately held cancer immunotherapy company, announced today the addition of several industry veterans to its executive team and advisory boards and the promotion of An Song, Ph.D. to Chief Scientific Officer from Senior Vice President of Development Sciences. Dr. Paul Woodard joins Immune-Onc from Bellicum Pharmaceuticals, Inc. where he most recently served as Senior Vice President, Clinical and Medical Affairs.

We are thrilled to add such seasoned and strategic individuals to the executive and advisory teams guiding Immune-Onc through its next phase of growth as a clinical stage company, said Charlene Liao, Ph.D., Co-founder and Chief Executive Officer of Immune-Onc. As our Chief Medical Officer, Paul brings the right combination of deep expertise in oncology paired with proven strategic leadership and experience building teams and functions in a startup environment. The appointment of An to Chief Scientific Officer is a reflection of the contributions she has already made to the company in her current role and a recognition of the value that her experience will bring in guiding the translation of our science into development.

I cant imagine a more exciting time to join Immune-Onc, said Dr. Woodard. I was first drawn to the novel science underlying the portfolio. As I learned more about Immune-Onc and their authentic passion for improving patient lives, it became clear to me that this was a company that I wanted to contribute to in a meaningful way with the goal of bringing much needed new treatment options to people with hard-to-treat cancers like acute myeloid leukemia.

About Paul Woodard, M.D.

As Chief Medical Officer, Dr. Woodard will be responsible for clinical leadership and medical oversight of the Immune-Onc portfolio. These activities will include review and input of IND submissions, clinical protocol development and medical oversight of Immune-Onc trials, and oversight of internal and external clinical development, biometrics, safety, and regulatory functions and compliance.

Dr. Woodard has an extensive hematology and oncology background gained in academia and industry. His academic experience focused on pediatric hematopoietic stem cell transplantation and hematologic disorders at world-renowned institutions, including St. Jude Childrens Research Hospital, University of California, San Francisco, and Childrens Hospital, Los Angeles. In addition to patient care, at St. Jude, Dr. Woodard was responsible for Phase 1/2 trials in pediatric hematopoietic stem cell transplantation for malignant and non-malignant disorders.

Prior to joining Immune-Onc, Dr. Woodard worked on a wide range of drug development projects in solid tumors, hematologic malignancies, and non-malignant hematologic disorders. At Exelixis, Dr. Woodard worked on small molecule tyrosine kinase inhibitors for solid tumors. At Amgen, Dr. Woodard was the global development leader for Nplate (romiplostim) in immune thrombocytopenia and myelodysplastic syndromes. At Genentech, Dr. Woodard was the global development team leader for Tecentriq (atezolizumab) in hematologic malignancies and was an integral team member for the development of Tecentriq combinations in solid tumors (including triple negative breast cancer) and hematologic malignancies. At Bellicum, Dr. Woodard was the Senior Vice President of Clinical and Medical Affairs, with oversight of the companys cellular therapy portfolio and clinical trials in hematologic malignancies and solid tumors.

Dr. Woodard earned his medical degree at the University of North Carolina and completed his residency at the University of Virginia and fellowships in pediatric hematology-oncology at the University of North Carolina and in pediatric blood and marrow transplantation at the University of Minnesota.

About An Song, Ph.D.

Dr. Song joined Immune-Onc in July 2018 as Senior Vice President of Development Sciences. In the newly created role of Chief Scientific Officer, Dr. Song will have overall accountability for translational development of Immune-Oncs portfolio and strategic oversight of research and antibody engineering.

Dr. Song is a translational scientist with 22 years of experience across basic research and drug development in oncology, autoimmunity, metabolic, infectious, and neurodegenerative diseases. Dr. Song joins Immune-Onc from Genentech where, as a Senior Director in BioAnalytical Sciences, she led the Assay Development and Technology group for the companys large molecule portfolio globally and was a member of numerous scientific review bodies within the Genentech Research and Early Development (gRED) organization. During her 16-year tenure at Genentech, Dr. Song contributed to, and oversaw 40+ IND/CTA and BLA/MAA regulatory filings for products including Rituxan, Avastin, Herceptin, Lucentis, Kadcyla and Tecentriq. In addition, Dr. Song played a significant role in the development and approval of Ocrevus.

Dr. Song received her Ph.D. in Biochemistry & Molecular Biology from Indiana University and completed a postdoctoral fellowship in immunology, followed by a faculty position as Assistant Professor (Research) at Stanford University. As an active member of the American Association of Pharmaceutical Scientists (AAPS), Dr. Song has served as an executive member of the Biotech Section and chair of the Therapeutic Product Immunogenicity (TPI) Focus Group/Community.

BOARD APPOINTMENTS

In addition, Immune-Onc bolstered its cadre of advisors with the appointment of Zhengbin (Bing) Yao, Ph.D. to its Board of Directors and Gregory Cosma, Ph.D. to its Scientific Advisory Board. Both Bing and Greg bring significant experience in helping early-stage companies navigate the complexity of drug development, commented Dr. Liao. Bing and Gregs perspectives are invaluable in supporting Immune-Onc in our mission to deliver transformative therapies to cancer patients.

About Zhengbin (Bing) Yao, Ph.D.

Dr. Yao has more than 20 years of experience in the biopharmaceutical industry, with a proven track record of successfully leading the discovery and development of multiple biotherapeutics. Dr. Yao is currently Chairman of the Board and CEO of Viela Bio. Prior to this role, he was Senior Vice President, Head of Respiratory, Inflammation and Autoimmune iMED at MedImmune/AstraZeneca. During his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications. Previously, Dr. Yao also served as Senior Vice President, Head of Immuno-Oncology Franchise, AstraZeneca, as well as CEO for WuXi-MedImmune Joint Venture. Dr. Yao joined MedImmune in 2010 from Genentech, where he was the Head of Project Team Leaders for Immunology, Infectious Diseases, Neuroscience, and Metabolic Disease. He was Vice President and Head of Research for Tanox, before the company was acquired by Genentech in 2007. Dr. Yao also held several positions of increasing responsibility at Aventis and Amgen and currently serves on the Board of Directors for NexImmune. Dr. Yao received his Ph.D. in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.

About Gregory Cosma, Ph.D.

As a former executive at Genentech and Bristol-Myers Squibb, Dr. Cosma has a long track record of success leading companies in translating science into approved therapies. As Vice President of Research and Early Development at Genentech from 2010-2019, Dr. Cosma led the Safety Assessment organization comprising Toxicology, Pathology, Product Quality and Occupational Toxicology and Nonclinical Operations. He also chaired the Genentech Development Review Committee (DRC), overseeing nonclinical development of the Genentech pipeline from Research to First-in-Human studies. While at Bristol-Myers Squibb from 2003-2010, Dr. Cosma held roles as the Executive Director for Drug Safety Evaluation and as the Therapeutic Area Head for Metabolic Diseases. Prior to these roles, Dr. Cosma was a Research Fellow at Pharmacia-Pfizer and an assistant professor in the College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Dr. Cosma earned his doctorate in Pharmacology/Toxicology at the University of Kansas.

ABOUT IMMUNE-ONC THERAPEUTICS, INC.

Immune-Onc Therapeutics, Inc. (Immune-Onc) is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients. The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline built upon strategic collaborations and cutting-edge research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center. Its lead program, an antibody targeting LILRB4, is being developed to treat acute myeloid leukemia and other cancers. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies. For more information, please visit http://www.immune-onc.com.

View post:
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions - Business Wire

Anatomy of a Sale: ‘DISRUPTORS’ w/Sara Nestor of Verve (Part 2) (Exclusive) – The Tracking Board

The Tracking Board, in partnership with The Script Lab, is excited to present a new episode of ANATOMY OF A SALE.

For the season finale of Anatomy of a Sale, Sara Nestor of Verve returns to showcase the electrically charged pitch sale DISRUPTORS from Susan Fowler & Allison Schroeder. The project is currently in development at Lionsgate with Good Universe and Burr! Productions producing. The pitch was based on Susans February 2017 article reflecting on the sexual harassment she faced while working at Uber, which led to the ousting of its CEO Travis Kalanick, set Silicon Valley ablaze, and helped set the stage for a revolution. Susan would go on to be one of the five women featured on the cover of TIME Magazines Person of the Year issue for 2017, representing The Silence Breakers.

Sara takes us through the release and discovery of the article in a pre-#MeToo world, what her place was as an agent in helping guide and protect Susan, the delicacy required to find the right fit for a project of this magnitude in both the film and book spaces, and how to deal with what was looming on the horizon the Harvey Weinstein scandal.

Sara Nestor is an Agent at Verve Talent and Literary Agency. She was home grown at Verve, starting in the mailroom and working her way up to the Agent ranks on Verves Motion Picture Literary team. In her tenure at Verve, Sara has had the great pleasure of working with such multitalented, influential creators as author / journalist / whistleblower / activist Susan Fowler; two time Oscar-Winning screenwriter and producer Brian Currie; NYTimes Bestselling author / screenwriter / director / journalist Nick Bilton (Vanity Fair); screenwriter / author / director / podcaster / icon John August; and the award-winning screenwriter and producer Meredith Stiehm.

Be sure to check out Saras previous Anatomy of a Sale by clicking here.

Anatomy of a Sale centers on the story behind the story, as in each episode well hear from the industrys top executives, representatives and writers chronicling their journey from the birth of a script to its eventual success. Youll learn about the struggles of taking a project to market, the painstaking hours that go into breaking the narrative, the ups and downs of industry reception, and much more. So sit back, relax, and study the inner-workings of the Anatomy of a Sale.

This episode is produced by Emily Dell and edited by Rob Schultz. For more video content, head over to TSL 360: The #1 Screenwriting Education Video Library. Be sure to stay up to date on Sara Nestor and all spec and sale related news by subscribing now.

Check Out More Episodes of Anatomy of a Sale by following the links below!

See the original post here:
Anatomy of a Sale: 'DISRUPTORS' w/Sara Nestor of Verve (Part 2) (Exclusive) - The Tracking Board

Battle of the Bands winners mix hard work with passion – Daily Trojan Online

Lori Loughlins Lonely Hearts Club Band, featuring musicians JP Dabu, Niles Miller, Joe Aleshaiker and Bruno Pita (right to left), beat out the competiton at Ground Zeros annual Battle of the Bands. (Photo courtesy of JP Dabu)

What do you get when a biochemistry major, a journalism major, a business major and a civil engineering graduate start a band? It sounds like the beginning of a bad joke, but the four members of Lori Loughlins Lonely Hearts Club Band have proven otherwise. On Oct. 25, they competed against three other groups at USCs Battle of the Bands and won a $300 Amazon gift card as a testimony to their talent.

Lead vocalist and keyboardist Joseph Dabu, or JP, was scrolling through his Instagram feed when he saw the application for the contest. He immediately contacted his high school friend Bruno Pita, a biochemistry graduate student at UCLA who plays the bass. Pita then contacted fellow Bruin Joe Aleshaiker, a recent alumnus and civil engineering major.

Lastly, Dabu reached out to Niles Miller, a junior majoring in business of cinematic arts who he met at Remedy Through Music, a student organization dedicated to visiting local hospitals and retirement homes and playing songs for the patients, nurses and visitors.

Before they even started playing, what first characterized their personality was their groups name witty, original and just a little bit controversial.

We couldnt come up with a name. We had a placeholder name [The Rivals] which was terrible, Pita said. I was actually ashamed of going up on stage like that I couldnt think of anything that was acceptable, Pita said.

On the last day the band was able to change its name for the competition, Pita desperately pulled up the Los Angeles Times and saw a headline about Lori Loughlins indictment. A lightbulb went off in his head. The alliteration of the three Ls was brilliant, and the callback to the quintessential Beatles album worked perfectly.

Its funny because both Bruno and Joe are from UCLA and Niles and I are from USC, Dabu said.

But Pita hopes no ones feelings were hurt.

I like to think of it as making your food spicy, Pita said. It might sting a bit but it makes the food more interesting to eat.

Although the spice in their name is certainly ear-catching, the food or in this case, their music is what kept the audience enthralled and eventually led them to victory. Their renditions of Dont Let Me Down, Something and Somebody to Love showcased their skills as musicians and proved that you dont have to major in music to find your passion in music.

Aleshaiker is living proof of this. Since graduating, he has been working on his music full time.

Ive been playing since I was 9 years old, so its always been a passion of mine, he said. For me at least, its definitely a big part of my life.

Likewise, Miller, the bands drummer, said his passion for music has always been present in his life. He learned to play the djembe and bongos with his dad and went on to play percussion and drums in middle school and high school.

I did do jazz ensemble for about a year, but then I stopped because it was too much with my current workload, Miller said. However, he still considers playing the drums a great passion.

Pita, on the other hand, only started playing music his junior year, learning to play the piano on an iPad app and eventually picking up the guitar. But unlike his bandmates, Pita mostly sees the instrument as a stress-relieving hobby.

Thats how we actually started jamming together, he was just so hyped I think to have someone that played with him, Pita said.

Even though Lori Loughlins Lonely Hearts dont identify as a Beatles cover band, the undertone and general respect for the iconic group is clear in their bands style, and each member identifies with an individual Beatle.

Im George, 100%, Aleshaiker said. I feel like George is always kind of in the background but is always contributing.

The other three have yet to reach some consensus. Bruno says hes a Paul because he plays the bass and sings the higher harmonies. Dabu says hes a Paul because hes left-handed. And although one might be tempted to call the drum player a Ringo, Miller objected.

I decided to leave it up to the BuzzFeed quiz on there, Miller said. And I got that Im a Paul!

Even though Lori Loughlins Lonely Hearts Club Band started out as a one-time performance, their win at Battle of the Bands was a definite confidence booster.

There was a lot of good competition, so I was actually kind of surprised that we won, Aleshaiker said.

Dabu agreed and lauded the other three bands they competed against.

We just banded together in September and the other bands Im sure, had been established, and probably were practicing more often than we were, he said.

But Natalie Williams, a freshman majoring in art who attended Battle of the Bands, dismisses their humble remarks.

I wasnt really surprised they won, she said. They had a lot of energy and were really hyped up. It was obvious they practiced a lot.

In the end, it wasnt just their hard work but their passion for music indisputably paid off.

We just wanted to have a good time, Dabu said. Im glad we did that.

Visit link:
Battle of the Bands winners mix hard work with passion - Daily Trojan Online

UNL students give their thoughts on impeachment hearings – Daily Nebraskan

Impeachment hearings are underway on Capitol Hill as the U.S. House of Representatives Permanent Select Committee on Intelligence works to decide if there will be an impeachment trial for President Donald Trump. The Daily Nebraskan asked students if they have been paying attention to the hearings and if they think impeachment is likely.

Pierce Leef, sophomore biochemistry and science education double major

Pierce Leef, sophomore biochemistry and science education double major

I havent been really paying attention. Ive wanted to, but theres a lot of other stuff going on right now, and its really busy. I personally hope that there is something involved with at least the process of going through and seeing what actually has happened and what hasnt because theres been a lot of misinformation on both sides. Just figuring out the real truth would be good.

Cleopatra Babor, freshman plant biology major

Cleopatra Babor, freshman plant biology major

I have been paying attention, and I believe that impeachment is very unlikely. Just all the information [President Trump] has been hiding is probably the most shocking thing, but in my personal opinion, we kind of all already knew [he was hiding information]. Its very close to the 2020 election and thats why I think impeachment is pushing to the unlikely side. But theres still hope.

Louis Lu, junior actuarial science major

Louis Lu, junior actuarial science

I havent been paying attention. For me, I am not really sure about politics in America because I dont really care about that because Im a Chinese student. Maybe [impeachment] is possible.

Alex Bartels, junior advertising and public relations major

Alex Bartels, junior advertising and public relations major

I have not been paying attention to the impeachment hearings. I just dont really pay attention to politics and dont really follow anyone on social media that talks about politics. I dont know much about it and also just dont really know if [impeachment] is possible or not. I feel like they probably wont impeach since the election is already coming up next year.

Ali Mohamed, junior education major

Ali Mohamed, junior education major

Ive seen clips here and there, but I havent been really paying attention. [Impeachment] is probably not going to happen. Its been going on for a while, and I feel like theyre dragging it on. By that time, hes probably going to be out of the office.

news@dailynebraskan.com

Read the original here:
UNL students give their thoughts on impeachment hearings - Daily Nebraskan

Longhorn Stop the Bleed receives 5 years of funding to expand emergency response training – UT The Daily Texan

The previously unfunded Longhorn Stop the Bleed program recently received five years of funding from Campus Safety and Security.

The program is a chapter of a national organization created after Sandy Hook to teach people how to respond in bleeding emergencies. UT alumna Claire Zagorski said she started a chapter of the program on campus to reduce fatality and helplessness.

I was inspired to bring it to UT after Harrison Brown was stabbed to death, program director Zagorski said. The bystander was saying, This is terrible because he was laying there bleeding and no one could do anything, just wait. Im a paramedic, and I knew that wasnt true, but I also knew people had to be taught what to do.

Zagorski said the funding will consist of $2,500 every year and is the result of safety advocacy nonprofit SafeHorns stressing the programs importance to Campus Safety and Security.

It was very validating, Zagorski said. Im glad that the work that were doing is getting noticed and that were making a difference, and now were going to be able to take a big step forward in expanding the program because of that.

Zagorski said the program will use the funds to buy more training equipment for larger classes and to launch a promotional campaign to increase awareness. She said the training is useful in many contexts, but people pay attention to the program if they see a recent uptick in campus violence.

UT is an open campus, biochemistry sophomore Sonia Patel said. I think its a necessity for people, and students especially, to be aware of what to do in the event of a shooting or stabbing. If we were aware of it, we could help save people.

Zagorski said the program partners with the certified EMTs in Longhorn EMS to lead training courses. David Wu, lead instructor of Longhorn Stop the Bleed in Longhorn EMS, said empowerment is a huge goal of the training.

It isnt necessarily having the skills, biochemistry junior Wu said. Its having the confidence of knowing you have the training to know what to do in that scenario. Most bystanders are in shock when something happens, and with a little training, it gives you a bit of confidence to go, Okay, I know what to do in this situation. This is how I should move forward.

Read more:
Longhorn Stop the Bleed receives 5 years of funding to expand emergency response training - UT The Daily Texan

Genetic Alterations Caused by Cancer Therapies Are Identified – Technology Networks

Living implies change. This is what happens to the cells of our bodies as we grow older: they accumulate genetic alterations, most of which are harmless. However, in some specific cases, these mutations can affect certain genes and can lead to the development of cancer. The source of these alterations can be exogenous (e.g., solar radiation, tobacco smoke or some toxic substance) or endogenous (e.g., errors in DNA processing).

Scientists led by ICREA researcher Nria Lpez-Bigas, head of the Biomedical Genomics Laboratory at the Institute for Research in Biomedicine (IRB Barcelona) and Assistant Professor at the Pompeu Fabra University, have characterized for the first time the genetic alterations caused by six therapies widely used for the treatment of cancer (five based on drugs used as chemotherapies, and radiotherapy).

Chemotherapies have revolutionized the treatment of cancer, allowing the survival of large numbers of patients. Some of these therapies kill cancer cells by damaging their DNA. However, these drugs can also harm the healthy cells of the patient, thereby explaining their side effects.

It is important to remember that chemotherapies are highly efficient for the treatment of cancer, says Oriol Pich, first author of the study. But long-term side effects have also been reported in some patients. Studying the DNA mutations that occur in cells as a result of chemotherapies is the first step towards understanding the relationship between these mutations and the long-term side effects of these treatments.

To carry out the study, the Hartwig Medical Foundation in the Netherlands provided the scientists with the sequences of the metastatic tumors of around 3,500 patients and information about the treatments that they received. Using bioinformatics techniques, Lpez-Bigas group has been able to identify a specific pattern of mutations in the metastatic tumors of the patients for each of the most widely used therapiestheir mutational footprint.

Once this footprint has been identified, we can quantify the DNA mutations that have been caused by each kind of chemotherapy, as well as those caused by treatment combinations, explains Lpez-Bigas. We have compared these numbers with the genetic alterations caused by natural endogenous processes. We have calculated that, during treatment, some of these chemotherapies cause DNA mutations at a rate that is between 100 and 1000 times faster than what normally occurs in a cell.

This knowledge will allow the optimization of cancer treatments. The aim is to maximize the beneficial effects of chemotherapies by destroying tumor cells while minimizing the number of mutations caused in the healthy cells of the patients. This would be achieved through a careful combination of dose and treatment duration, says Lpez-Bigas.

Reference

Pich et al. (2019) The mutational footprints of cancer therapies. Nature Genetics. DOI: https://doi.org/10.1038/s41588-019-0525-5

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read the original here:
Genetic Alterations Caused by Cancer Therapies Are Identified - Technology Networks

Ash dieback: Genetic resistance offers new hope over unstoppable disease expected to kill 70 per cent of species – The Independent

A devastating fungal disease, the cause of ash dieback, is on course to decimate Europes ash trees, with 70 million in the UK currently expected to perish over the coming years, costing the economy an estimated 15bn.

But in some pockets of woodland, resistance to the sickness has been detected, offering a glimmer of hope that ash trees will not be permanently erased from the landscape.

Scientists sequenced whole genomic DNA from 1,250 ash trees in 31 different areas in order to identify the inherited genes associated with ash dieback resistance.

Sharing the full story, not just the headlines

The study, published in the journal Nature Ecology & Evolution, shows resistance is controlled by several genes, offering hope survivors could be used to restore diseased woodlands, either by natural regeneration or selective breeding.

Professor Richard Nichols, author of the study from Queen Mary University of London, said: We found that the genetics behind ash dieback resistance resembled other characteristics like human height, where the trait is controlled by many different genes working together, rather than one specific gene.

Overall winner of the competition

Csaba Daroczi/NPOTY 2019

Winner in the Underwater category

Alexey Zozulya/NPOTY 2019

Finalist in the Mammals category

Jose Juan Hernandez/NPOTY 2019

Finalist in the Man and Nature category

Tom Svensson/NPOTY 2019

Finalist in the Mammals category

Marcio Cabral/NPOTY 2019

Winner of the Youth category

Giacomo Redaelli/NPOTY 2019

Finalist in the Man and Nature category

Britta Jaschinski/NPOTY 2019

Finalist in the Other Animals category

Wei Fu/NPOTY 2019

Finalist in the Landscapes category

Brandon Yoshizawa/NPOTY 2019

Finalist in the Man and Nature category

Pedro Narra/NPOTY 2019

Overall winner of the competition

Csaba Daroczi/NPOTY 2019

Winner in the Underwater category

Alexey Zozulya/NPOTY 2019

Finalist in the Mammals category

Jose Juan Hernandez/NPOTY 2019

Finalist in the Man and Nature category

Tom Svensson/NPOTY 2019

Finalist in the Mammals category

Marcio Cabral/NPOTY 2019

Winner of the Youth category

Giacomo Redaelli/NPOTY 2019

Finalist in the Man and Nature category

Britta Jaschinski/NPOTY 2019

Finalist in the Other Animals category

Wei Fu/NPOTY 2019

Finalist in the Landscapes category

Brandon Yoshizawa/NPOTY 2019

Finalist in the Man and Nature category

Pedro Narra/NPOTY 2019

Now we have established which genes are important for resistance we can predict which trees will survive ash dieback. This will help identify susceptible trees that need to be removed from woodlands, and provide the foundations for breeding more resistant trees in future.

Samples were collected from ash trees in a Forest Research mass screening trial, which comprises 150,000 trees across 14 sites in southeast England.

The researchers screened for resistance genes using a rapid approach where the DNA of diseased and unaffected trees was separated.

Many of the genes found to be associated with ash dieback resistance were similar to those previously shown to be involved in disease or pathogen responses in other species.

Ash dieback is a major threat to the UK landscape. According to the Woodland Trust, the effects will be staggering.

It will change the landscape forever and threaten many species which rely on ash, the trust has warned.

The fungus Hymenoscyphus fraxineusaffects ash trees of any age and in the UK between 70 and 95 per cent of ash trees are expected to succumb.

The 15bn economic impact is expected to be greater than that of the 2001 foot-and-mouth disease outbreak which led to more than 6 million cattle and sheep being exterminated, according to an assessment this year by a team from Oxford University.

The predicted costs include clearing up dead and dying trees, but also lost benefits provided by the trees, including water and air purification and carbon sequestration.

The loss of these services is expected to be the biggest cost to society, while millions of ash trees also line Britains roads and urban areas, and clearing up dangerous trees will cost billions of pounds.

The disease has spread throughout Europes ash populations, and was first recorded in the UK in 2012.

Professor Richard Buggs, senior research leader in plant health at the Royal Botanic Gardens, Kew and lead author of the paper, said: There is no cure for ash dieback and it threatens to kill over half of the 90 million ash trees in the UK. This will have huge impacts on the British landscape.

Our new findings of the genetic basis of natural resistance found in a small minority of British ash trees help us to predict how ash populations will evolve under ash dieback. While many ash trees will die, our findings are encouraging from a long-term perspective and reassure us that ash woodlands will one day flourish again.

Original post:
Ash dieback: Genetic resistance offers new hope over unstoppable disease expected to kill 70 per cent of species - The Independent

A Rare Genetic Disorder Turned These Siblings’ Blood ‘Milky’ White – Livescience.com

A rare genetic disorder caused three siblings' blood to flood with fat and turn "milky" white, according to a new report of the unusual case.

The three siblings consisted of one set of fraternal twins (a daughter and son) and an older son, all born to a first-cousin couple in a Pennsylvania Dutch family. In their teens and early 20s, all three siblings experienced mysterious symptoms, including bouts of abdominal pain. They had all been diagnosed with hypertriglyceridemia, a fairly common disorder that causes fatty molecules called triglycerides to build up in the blood.

Now in their 50s, the siblings recently underwent genetic testing and learned that they have a condition that's much more rare, affecting only 1 in every million people, according to the case report, published today (Nov. 18) in the journal Annals of Internal Medicine.

Those with the ultrarare disorder, known as familial chylomicronemia syndrome (FCS), may accumulate more than 1,000 milligrams of triglycerides per deciliter (mg/dL) of blood. For comparison, normal blood levels of the fat should fall below 150 mg/dL, and 500 mg/dL would be considered "very high" in a healthy person, according to the National Institutes of Health.

Indeed, in people with FCS, blood fat levels are so high that the normally crimson fluid turns the color of milk. (FCS is not the only condition that can cause milk-colored blood; the symptom may also appear in people with severe hypertriglyceridemia.)

Related: The Color of Blood: Here Are Nature's Reddest Reds (Photos)

The three siblings had long struggled to keep their triglyceride levels under control and suffered frequent inflammation of the pancreas, also known as pancreatitis a serious condition that can cause abdominal pain, fever and vomiting. At the hospital, the male twin's triglyceride levels reached as high as 5,000 mg/dL, while the other brother's levels peaked at around 6,000 mg/dL. The female twin's triglyceride levels soared highest of all, reaching 7,200 mg/dL at maximum.

The siblings hoped their doctors could help subdue those aggressive symptoms.

To confirm the sibling's rare diagnosis, the doctors looked to their patients' genes. Triglycerides typically build up in the blood due to multiple malfunctioning genes and other related health conditions, such as diabetes or high-blood pressure, according to the Journal of the American Board of Family Medicine. But when doctors probed the siblings' genetic code, the researchers spotted only one mutated gene that was key for breaking down triglycerides in the body.

In healthy people, the gene contains instructions to build a protein called lipoprotein lipase (LPL), which typically coats the blood vessels that run through muscles and fatty tissues in the body, according to the Genetics Home Reference. LPL breaks down fats carried in the blood; without an adequate supply, the siblings' blood plasma ran thick with excess triglycerides.

Related: How to Speak Genetics: A Glossary

Each sibling carried two copies of the mutated LPL gene, meaning both their parents passed down the mutated genetic code to the children, the case report noted. What's more, the particular genetic mutation in the siblings had never been seen before, the authors said. The doctors placed the siblings on a fat-restricted diet, which successfully stabilized their triglyceride levels and quelled their bouts of pancreatitis. Sometimes, when triglyceride levels spike, doctors must manually replace the fat-filled blood of their patients with healthy blood from donors, Live Science previously reported. Thankfully, the siblings' condition could be curtained with diet alone.

Originally published on Live Science.

Want more science? Get a subscription of our sister publication "How It Works" magazine, for the latest amazing science news.

(Image credit: Future plc)

More:
A Rare Genetic Disorder Turned These Siblings' Blood 'Milky' White - Livescience.com

Finding Mutations On These 49 Genes May Help Prevent Sudden Cardiac Death – WBUR

For most patients,sudden cardiac death iscompletely unexpected, according toDr. Amit Khera, a cardiologist at Massachusetts General Hospital.

Its always particularly devastating because many dont have prior symptoms. Their first symptom is actually dropping dead, Khera said. The question is can we find these people before something really bad happens?

Many scientists, including Khera, theorizedthat one way to find people who might suffer these sudden cardiac deaths fatal events related to an abrupt cardiovascular failure could betheir genetics.

We always had a hunch that maybe there was something in their DNA that predisposed them to this tragedy, he said.

Now, he and his colleagues believe theyve found 14 different gene variants, spread across seven genes that may put their carriers at greater risk for sudden heart death.

The researchers made this discovery by sequencingthe genes of 600 people who died from sudden cardiac death and600 people of the same age whowere healthy. Khera said they focused on 49 genesalreadyknown to be important for cardiovascular disease.

These genes contribute to any of the four major causes [for sudden cardiac death], he said. Sometimes its a weak heart and the pumping function is not quite right. The second is a heart attack. The third is a problem with the hearts rhythm. The last is a tear in a major blood vessel.

After a geneticist on the team analyzed the genetic data, Khera said 14 different versions of 7 genes stood out.

These 14 variants were found in 15 people. Whats really striking is that all 15 people were sudden cardiac death cases and zero were [healthy], he explained.

The team reported their findings Saturday in the Journal of the American College of Cardiology.

After identifying the specific gene variants, theresearchers looked ata larger database of 4,000 individuals. They found that about 1% of the population without a history of heart disease carries similar mutations in one of the 49 genes scientists believe are critical to heart health.

Its a really small percent of people, but an important percent," said Khera. "These people are predisposed to sudden cardiac death, and if we can find them then we have tools to prevent disease onset.

Carrying one of those mutations doesnt mean a person is certain to suffer from sudden cardiac death, Khera says. But his analysis suggests they do make the event three times more likely over a period of 15 years.

In most cases, doctors saysudden cardiac death arises from preventable causes.

Most of the gene variations underlying [sudden cardiac death] are related to the electrical rhythm of the heart going chaotic or haywire," said Dr. Eric Topol, vice president of Scripps Research and a cardiologist who did not work on the study.

"There are many ways you can prevent this occurrence if you know a person has a high risk mutation, Topol said. Medications or a device like a defibrillator or pacemaker can fix the underlying problem.

There are likely many more mutations that increase the risk for sudden cardiac death.

The more we find of these, the more confident we are that they are the real deal, the better we will, in the future, be at preventing these catastrophes, Topol said. So, I think this is really important work.

And not every sudden cardiac death strikes healthy individuals with no previous history of heart disease, Khera added.

Of course, important lifestyle factors play a role, like smoking over the course of a lifetime or not well controlled blood pressure, he said.

But often, families and friends of those who die from sudden cardiac death dont get a reason for why it happened.

The DNA can provide an explanation as to why this happened, Khera said. And even more importantly, this persons family members may also have the gene variant, and if they know about it then they can take preventative measures.

Editor's note: There are many mutations in the 49 genes researchers looked at in this study that may increase the risk of sudden cardiac death. Those "disease-causing" mutations occur in roughly 1% of the population, according to the research. The study focused on 14 of them.

The rest is here:
Finding Mutations On These 49 Genes May Help Prevent Sudden Cardiac Death - WBUR